Skip to main content
. 2019 May 7;39(5):BSR20181374. doi: 10.1042/BSR20181374

Figure 4. The feasibility of using plasma miR-20a-5p level as a predict tool for gemcitabine resistance of pancreatic cancer.

Figure 4

(A) qRT-PCR of plasma miR-20a-5p in patients with or without gemcitabine resistance. (B) qRT-PCR of tissue miR-20a-5p in patients with or without gemcitabine resistance. (C) ROC curve for plasma miR-20a-5p level as a predict tool for gemcitabine resistance in pancreatic cancer. (D) Kaplan–Meier analysis for PFS in pancreatic cancer patients with high and low expression level of miR-20a-5p; **P<0.01.